

Abstract

Treatment of Neuropathy

This invention relates to the use of cyclic guanosine 3', 5'-monophosphate
5 phosphodiesterase type five (cGMP PDE5) inhibitors, including in particular the
compound sildenafil, for the treatment of neuropathy, including in particular the
treatment of diabetic neuropathy.